RBC Capital raised the firm’s price target on 4D Molecular to $40 from $35 and keeps an Outperform rating on the shares. The firm notes that discussions with a key opinion leader regarding the company’s wAMD program was bullish, though that regarding cystic fibrosis was “more neutral”. With the recent pullback of 27% since its cystic fibrosis regulatory update however, RBC sees a good entry point ahead of upcoming catalysts, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular assumed with a Buy at Jefferies
- 4D Molecular price target lowered to $63 from $70 at BMO Capital
- 4D Molecular announce update on regulatory interactions, development for 4D-710
- 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
- 4DMT to Participate in Upcoming Investor Conferences
